Lumen Technologies hires Sean Alexander as head of Connected Ecosystems
Arcus Biosciences Inc (NYSE:RCUS) stock has reached a 52-week low, trading at $9.42, as the company faces a challenging market environment. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.5x, though it’s currently trading below its Fair Value. This price level reflects a significant downturn from the previous year, with the stock experiencing a 1-year change of -46.75%. Investors are closely monitoring the company’s performance and potential catalysts that could influence its stock price in the coming months, with analyst price targets ranging from $17 to $46 per share. InvestingPro subscribers have access to 12 additional key insights about RCUS’s financial health and market position. The current low presents a critical moment for Arcus Biosciences, as market participants consider the stock’s valuation and future prospects in the biotechnology sector. While the company holds more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn and anticipated sales decline in the current year.
In other recent news, Arcus Biosciences announced a substantial cash position of approximately $992 million as of December 31, 2024. The company retains full global development and commercial rights to its cancer drug casdatifan, following the expiration of Gilead Sciences (NASDAQ:GILD)’ option to license the drug. Arcus Biosciences has also disclosed new data from its ARC-20 study, showing a median progression-free survival of 9.7 months for patients with metastatic clear cell renal cell carcinoma at a 50 mg twice daily dosage. The overall response rates for the study were 25% for the 50 mg BID cohort, 32% for the 50 mg QD cohort, and 33% for the 100 mg QD cohort. Additionally, Arcus Biosciences has initiated a $150 million stock offering to fund the continued development of casdatifan and other corporate purposes. H.C. Wainwright recently adjusted its price target for Arcus Biosciences shares to $18, maintaining a Neutral rating. Meanwhile, H.C. Wainwright analyst Emily Bodnar upgraded the stock rating from Neutral to Buy, citing the potential of the casdatifan and cabozantinib combination therapy. Arcus Biosciences plans to start the Phase 3 PEAK-1 trial in the second quarter of 2025 to further evaluate casdatifan’s efficacy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.